19 related articles for article (PubMed ID: 29394779)
1. A microarray expression profile and bioinformatic analysis of circular RNA in human esophageal carcinoma.
Cai S; Zhang Y; Zhang X; Wang L; Wu Z; Fang W; Chen X
J Gastrointest Oncol; 2022 Apr; 13(2):510-526. PubMed ID: 35557573
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
3. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis.
Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M
Oncology; 2024; 102(3):228-238. PubMed ID: 37708864
[TBL] [Abstract][Full Text] [Related]
7. [Outcome of Patients with Pathological Complete Response after Neoadjuvant Chemotherapy in Advanced Esophageal Cancer].
Hikami S; Shiozaki A; Fujiwara H; Konishi H; Arita T; Kosuga T; Morimura R; Murayama Y; Komatsu S; Ikoma H; Kuriu Y; Nakanishi M; Ichikawa D; Okamoto K; Otsuji E
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1796-1798. PubMed ID: 29394779
[TBL] [Abstract][Full Text] [Related]
8. [Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].
Oyanagi H; Ichikawa H; Kosugi S; Banba T; Hanyu T; Hirashima K; Ishikawa T; Kameyama H; Kobayashi T; Minagawa M; Koyama Y; Wakai T
Gan To Kagaku Ryoho; 2015 Apr; 42(4):497-501. PubMed ID: 25963701
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.
Watanabe M; Nagai Y; Kinoshita K; Saito S; Kurashige J; Karashima R; Hirashima K; Sato N; Imamura Y; Hiyoshi Y; Baba Y; Iwagami S; Miyamoto Y; Iwatsuki M; Hayashi N; Baba H
Digestion; 2011; 83(3):146-52. PubMed ID: 21266808
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]